Chelsea Film Festival

Brian Mehling, M.D. hosted a gathering for filmmakers during the Chelsea Film Festival at his home in New York City on Friday October 15, 2021.
Dr. Mehling is also a documentary film producer. He is president and CEO of Industrial Motion Pictures (IMP), producer of the film Tiny Tears, which debuted at the prestigious Cannes Film Festival. Their newest film, titled “Stem Cells: The Revolution Is Here” was part of the Chelsea Film Festival this year.

DrBrianMehling #BlueHorizonStemCells

ChelseaFilmFestival #CFFNY2021

Brian Mehling, MD presented at the Annual Congress of Society for Brain Mapping & Therapeutics in Los Angeles

World leading translational neuroscience foundation highlighted the pioneering scientific, technological, advocacy, and policy work at the Ritz Carlton/JW Marriott in Downtown LA on July 10, 2021

The conference was the first in-person major medical conference in California after the state reopened.
Dr. Brian Mehling is the founder and chief medical officer of BHI Therapeutic Sciences. He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells.
Dr. Mehling presented two talks in two sessions: “Session in Innovation in Spine Surgery” where his talk title was ” Umbilical Cord Blood Stem Cell Therapy for Spinal Cord Injury.”
The objective of this retrospective cohort study was to analyze the muscle, nerve, urinary, and gastrointestinal function in subjects with spinal cord injury, treated with either human umbilical cord blood-derived mononuclear cells or conventional therapy. “Allogeneic umbilical cord blood mononuclear cell therapy in 30 subjects with spinal cord injury showed significant improvement in pain and temperature sensation, lower limb muscle strength, bladder function, and gastrointestinal function compared to a conventional therapy group,” Dr. Mehling said.
The second session was in Neurovascular Disorders and Dr.Mehling talk’s title was “Stem Cells and Stroke Recovery: A Retrospective Study.” Dr. Mehling presented the results of a study using Human umbilical cord blood cell therapy to treat stroke. Ninety-seven research subjects with ischemic and hemorrhagic stroke showed significant improvement of mobility of upper and lower extremities, muscle strength of upper and lower limbs and neurological function after therapy.

In addition, Dr.Mehling co-chaired a stem cell session (Session A26 – Stem Cell).

BHI Therapeutic Sciences (BHITS) is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells (those that are harvesting from an umbilical cord in the case of a C-Section, bringing no injury or risk to mother or baby).
Stem cells are a special kind of cell that can be used to regenerate the human body
without drugs or surgery, treating the leading diseases and injuries shortening our life spans and causing millions of people to live in chronic pain.
Brain Mapping Foundation (BMF) was established in 2003 to help fast-tracking diagnostics and therapeutics for wounded soldiers, veterans, and civilians with neurological, spine, and neuro-psychiatric disorders. Since then, the organization has been pioneering lifesaving therapeutics and introducing trailblazing initiatives such as Neuroscience20 (Brain20, Spine20, Mental20) and Brain Technology and Innovation Park (BTIP) while celebrating pioneers in the fields.

Media Contact
Doreen Santora
[email protected]

Brian Mehling, M.D. presented at the Neuroscience 20 | SBMT virtual summit on November 21, 2020

The title of Dr. Mehling’s presentation is “Umbilical Cord Blood Stem Cell Therapy for Spinal Cord Injury.”
Spinal cord injury (SCI) is a common type of severe trauma often resulting in a permanent neurologic deficit. The current retrospective cohort study is aimed to analyze the muscle, nerve, urinary, and gastrointestinal function in SCI subjects treated with either human Umbilical Cord Blood Mononuclear Cells (hUCMNCs) or conventional therapy. Thirty patients with spinal cord injury were randomly selected from seventy treated with hUCMNCs between March 2009 and March 2012. Another thirty patients with SCI, who received only traditional therapy and no stem cell therapy, were included as the control group.
This study was approved by an Institutional Review Board of the Wright State University (Office of Research and Sponsored Programs. SC# 5488, “Spinal Cord Injury Stem Cell Therapy”).
A significantly higher proportion of subjects in the hUCMNCs therapy group showed improved function in pain and temperature sensation, lower limb muscle strength, bladder function, and gastrointestinal function compared to a conventional therapy group.
More information about the summit can be found here:

To view program please click below:

Paper from BHI Therapeutic Sciences and Blue Horizon International, Slovakia Published in the Journal of Clinical Medicine Research

Osteoarthritis is the most common form of arthritis, affecting millions of people worldwide. It happens when the protective cartilage that cushions your bones wears down over time. Osteoarthritis most commonly affects hands, knees, hips, and spine. Researchers and clinicians from BHI Therapeutic Sciences, USA and Blue Horizon International, Slovakia recently concluded cell-based therapy shows promising results in the regeneration of injured cartilage and serves as an anti-inflammatory for the affected joint.

The paper, “A Retrospective Study of Stromal Vascular Fraction Cell Therapy for Osteoarthritis” was recently published in the Journal of Clinical Medicine Research.

“Our study of 350 subjects with hip and knee osteoarthritis showed a significant improvement in pain levels and mobility at 3, 6, and 12 months compared to 7 days after autologous stromal vascular fraction (SVF) cell therapy,” said Brian Mehling, M.D., one of the authors of the study and the chief medical officer of BHI Therapeutic Sciences.

The study was approved by the Institutional Review Board of the Institute of Regenerative and Cellular Medicine (IRCM-2-17-137) and by the Ministry of Health of the Slovak Republic.

“The treatment demonstrated a strong safety profile with no severe adverse events or complications reported,” said Marina Manvelyan, Ph.D., clinical research scientist at BHI Therapeutic Sciences. “Interestingly, the results of the study show that SVF cell therapy was more effective in subjects with arthritis stage III compared to arthritis stages I, II, and IV,” she added.

The authors of the paper are Brian Mehling, Milan Hric, Adriana Salatkova, Robert Vetrak, Doreen Santora, Miriama Ovariova, Renata Mihalyova, and Marina Manvelyan.
BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.

The Journal of Clinical Medicine is an international, open access, and peer-reviewed journal that concentrates on general medical research and clinical practice. The journal aims to publish scientifically written, evidence-based articles from all disciplines of medical sciences and clinical practice, and nursing, preventive medicine, epidemiology, healthcare research, etc. All articles are rigorously peer-reviewed. The journal is indexed in PubMed and PubMed Central (PMC, US National Library of Medicine National Institutes of Health).

To read the study, visit

Nobel Prize for Chemistry given to 2 scientists for developing genome editing method

Researchers need to modify genes in cells if they are to find out about life’s inner workings. This used to be time-consuming, difficult and sometimes impossible work. Using the CRISPR/Cas9 genetic scissors, it is now possible to change the code of life over the course of a few weeks. Emmanuelle Charpentier and Jennifer A. Doudna have discovered one of gene technology’s sharpest tools: the CRISPR/Cas9 genetic scissors. Using these, researchers can change the DNA of animals, plants and microorganisms with extremely high precision. This technology has had a revolutionary impact on the life sciences, is contributing to new cancer therapies and may make the dream of curing inherited diseases come true.